Commentary: Genome-based CNS drug discovery: d-Amino acid oxidase (DAAO) as a novel target for antipsychotic medications: Progress and challenges

Biochemical Pharmacology

Volumn 78, Issue 11, 2009, Pages 1360-1365

  Williams, Michael ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antipsychotics; DAAO; Drug discovery; Drug targets; G72; Genomics; Schizophrenia

Indexed keywords

4H THIENO[3,2 B]PYRROLE 5 CARBOXYLIC ACID; 5 METHYL 3 PYRAZOLECARBOXYLIC ACID; 6 CHLOROBENZO[D]ISOXAZOL 3 OL; ARIPIPRAZOLE; AS 057278; ATYPICAL ANTIPSYCHOTIC AGENT; BENZOIC ACID; CHLORPROMAZINE; CLOZAPINE; DEXTRO AMINO ACID OXIDASE; DEXTRO AMINO ACID OXIDASE INHIBITOR; DEXTRO SERINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; HALOPERIDOL; ILOPERIDONE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; RISPERIDONE; SEP 227900; UNCLASSIFIED DRUG;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME REGULATION; GENETIC ASSOCIATION; GENOMICS; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; NEGATIVE SYNDROME; NEUROPATHIC PAIN; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TRANQUILIZING ACTIVITY;

EID: 70349776074     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.06.108     Document Type: Note

References (80)

1. Williams M. Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia. Curr Opin Invest Drugs 4 (2003) 31-36
2. Hardy J., and Singleton A. Genomewide association studies and human disease. N Engl J Med 360 (2009) 1759-1768
3. Vogelstein B, quoted in Hayden EC. Cancer complexity slows quest for cure. Nature 2008;455:148.
4. Williams H.J., Owen M.J., and O'Donovan M.C. New findings from genetic association studies of schizophrenia. J Hum Genet 54 (2009) 9-14
5. O'Donovan M.C., Craddock N., Norton N., Williams H., Peirce T., Moskvina V., et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 40 (2008) 1053-1055
6. Huffaker S.J., Chen J., Nicodemus K.K., Sambataro F., Yang F., Mattay V., et al. A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat Med 15 (2009) 509-518
7. Potkin S.G., Turner J.A., Fallon J.A., Kaetor D.B., Guffanti G., and Macciardi F. Gene discovery through imaging genetics: identification of two novel genes associated with schizophrenia. Mol Psychiatr 14 (2009) 416-428
8. Cantor R.M., and Geschwind D.H. Schizophrenia: genome, interrupted. Neuron 58 (2008) 165-167
9. Owen M.J., Williams H.J., and O'Donovan M.C. Schizophrenia genetics: advancing on two fronts. Curr Opin Genetics Develop (2009) 10.1016/j.gde.2009.02.008
10. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26 (2006) 365-384
11. Millan M.J. N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berlin) 179 (2005) 30-53
12. Carpenter Jr. W.T., Conley R.R., and Buchanan R.W. Schizophrenia. In: Enna S.J., and Coyle J.T. (Eds). Pharmacological Management of Neurological and Psychiatric Disorders (1998), McGraw-Hill, New York 27-51
13. Lindsay M. Target discovery. Nat Rev Drug Discov 2 (2003) 831-838
14. Kopec K., Bozyczko-Coyne D.B., and Williams M. Target identification and validation in drug discovery: the role of proteomics. Biochem Pharmacol 69 (2005) 1133-1139
15. Detera-Wadleigh S.D., and McMahon F.J. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol Psychiatry 60 (2006) 106-114
16. McGrath J., Saha S., Chant D., and Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30 (2008) 67-76
17. Wang K., Zhang H., Ma D., Bucan M., Glessner J.T., Abrahams B.S., et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature (2009) 10.1038/nature07999
18. Lewis D.A., and Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 25 (2003) 409-432
19. Marino M.J., Knutsen L.J.S., and Williams M. Emerging opportunities for antipsychotic drug discovery in the postgenomic era. J Med Chem 51 (2008) 1077-1107
20. Green M.F. Stimulating the development of drug treatments to improve cognition in schizophrenia. Annu Rev Clin Psychol 3 (2007) 159-180
21. Lieberman J.A., Stroup S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
22. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63 (2006) 1079-1087
23. Lewis S., and Liberman J. CATIE and CUtLASS: can we handle the truth?. Br J Psychiatry 192 (2008) 161-163
24. Taylor D.M. Antipsychotics and QT prolongation. Acta Psychiatr Scand 107 (2003) 85-95
25. McEvoy J., Meyer J., Goff D., Nasrallah H., Davis S., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80 (2005) 19-32
26. Hollingsworth C. Vanda shares surge 626% on FDA approval of Fanapt. BioWorld Today, 2009, 20 (88) May, 8, 2009, 1/3.
27. Herper M. Is The FDA Easing Up? Forbes.com. http://www.forbes.com/2009/05/07/fda-vanda-trials-business-health-care-antipsychotics.html; 2009.
28. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., and Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17 (1997) 141-150
29. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., et al. d-Serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57 (2005) 577-585
30. Yang C.R., and Svennson K.A. Allosteric modulation of NMDA receptor via elevation of brain glycine and d-serine: the therapeutic potential for schizophrenia. Pharmacol Ther 120 (2008) 317-332
31. Chumakov I., Blumenfeld M., Guerassimenko O., Cavarec L., Palicio M., and Abderrahim H. Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 99 (2002) 13675-13680
32. Korostishevsky M., Kaganovich M., Cholostoy A., Ashkenazi M., Ratner Y., Dahary D., et al. Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol Psychiatry 56 (2004) 169-176
33. Schumacher J., Jamra R.A., Freudenberg J., Becker T., Ohlraun S., Otte A.C., et al. Examination of G72 and d-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol Psychiatry 9 (2004) 203-207
34. Goldberg T.E., Straub R.E., Callicott J.H., Hariri A., Mattay V.S., and Bigelow L. The G72/G30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacology 31 (2006) 2022-2032
35. Liu X., He G., Wang X., Chen Q., Qian X., and Lin W. Association of DAAO with schizophrenia in the Chinese population. Neurosci Lett 369 (2004) 228-233
36. Shinkai T., De Luca V., Hwang R., Muller D.J., Lanktree M., Zai G., et al. Association analyses of the DAOA/G30 and d-amino-acid oxidase genes in schizophrenia: further evidence for a role in schizophrenia. Neuromol Med 9 (2007) 169-177
37. Ohnuma T., Shibata N., Maeshima H., Baba H., Hatanao T., Hanzawa R., Arai H., et al. Association analysis of glycine- and serine-related genes in a Japanese population of patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 33 (2009) 511-518
38. Hattori E., Liu C., Badner J.A., Bonner T.I., Christian S.L., Maheshwari M., et al. Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series. Am J Hum Genet 72 (2003) 1131-1140
39. Chen Y.S., Akula N., Detera-Wadleigh S.D., Schulze T.G., Thomas J., Potash J.B., et al. Findings in an independent sample support an association between bipolar affective disorder and the G72/G30 locus on chromosome 13q33. Mol Psychiatry 9 (2004) 87-92
40. Zhang Z., Li Y., Zhao Q., Huang K., Wang P., Li S., et al. First evidence of association between G72 and bipolar disorder in the Chinese Han population. Psychiatry Genet 19 (2009) 151-153
41. Jeon J.W.J., Chung S.H.C., Hong J.P.H., and Yoo H.I.Y. Association of DAO and DAOA genes with autism spectrum disorders in Korean boys. Eur Neuropsychopharmacol 16 Suppl. 4 (2006) S526
42. Yoshikawa M., Andoh H., Ito K., Suzuki T., Kawaguchi M., Kobayashi H., Oka T., and Hashimoto A. Acute treatment with morphine augments the expression of serine racemase and d-amino acid oxidase mRNAs in rat brain. Eur J Pharmacol 525 (2005) 94-97
43. Yue W., Liu Z., Kang G., Yan J., Tang F., Ruan Y., et al. Association of G72/G30 polymorphisms with early-onset and male schizophrenia. Neuroreport 17 (2006) 1899-1902
44. Liu Y.L., Fann C.S., Liu C.M., Chang C.C., Wu J.Y., Hung S.I., et al. No association of G72 and d-amino acid oxidase genes with schizophrenia. Schizophr Res 87 (2006) 15-20
45. Williams N.M., Green E.K., Macgregor S., Dwyer S., Norton N., Williams H., et al. Variation at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorder. Arch Gen Psychiatry 63 (2006) 366-373
46. Kvajo M., Dhilla A., Swor D.E., Karayiorgou M., and Gogos J.A. Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function. Mol Psychiatr 13 (2008) 685-696
47. Ohi K., Hashimoto R., Yasuda Y., Yoshida T., Takahashi T., Iike N., et al. Association study of the G72 gene with schizophrenia in a Japanese population: a multicenter study. Schizophr Res 109 (2009) 80-85
48. Li D., and He L. G72/G30 genes and schizophrenia: a systematic meta-analysis of association studies. Genetics 175 (2007) 917-922
49. Shi J., Badner J.A., Gershon E.S., and Liu C. Allelic association of G72/G30 with schizophrenia and bipolar disorder: a comprehensive meta-analysis. Schizophr Res 9 (2008) 89-97
50. Saachi S., Bernasconi M., Martineau M., Mothet J.-P., Ruzzene M., Pilone M.S., et al. pLG72 modulates intracellular d-serine levels through its interaction with d-amino acid oxidase. Effect on schizophrenia susceptibility. J Biol Chem 283 (2008) 22244-22256
51. Schell M.J., Molliver M.E., and Snyder S.H. d-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc Natl Acad Sci USA 92 (1995) 3948-3952
52. Almond S.L., Fradley R.L., Armstrong E.J., Heavens R.B., Rutter A.R., Newman R.J., et al. Behavioral and biochemical characterization of a mutant mouse strain lacking d-amino acid oxidase activity and its implications for schizophrenia. Mol Cell Neurosci 32 (2006) 324-334
53. Maekawa M., Watanabe M., Yamaguchi S., Konno R., and Hori Y. Spatial learning and long-term potentiation of mutant mice lacking d-amino-acid oxidase. Neurosci Res 53 (2005) 34-38
54. Madeira C., Freitas M.E., Vargas-Lopes C., Wolosker H., and Panizzutti R. Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res 101 (2008) 76-83
55. Hashimoto K., Fukushima T., Shimizu E., Komatzu N., Watanabe H., Shinoda N., et al. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60 (2003) 572-576
56. Boks M.P., Rietkerk T., van de Beek M.H., Sommer I.E., de Koning T.J., and Kahn R.S. Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia. Eur Neuropsychopharmacol 17 (2007) 567-572
57. Pollegioni L., Piubelli K., Sacchi S., Pilone M.S., and Molla G. Physiological functions of d-amino acid oxidases: from yeast to humans. Cell Mol Life Sci 64 (2007) 1373-1394
58. Konno R., and Yasumura Y. Mouse mutant deficient in d-amino acid oxidase activity. Genetics 103 (1983) 277-285
59. Krug A.W., Volker K., Dantzler W.H., and Silbernagl S. Why is d-serine nephrotoxic and AIB (α-amino-iso-butyric acid) protective?. Am J Physiol Renal Physiol 293 (2007) F382-F390
60. Vanconi M.A., Cosma A., Mazzeo D., Mattevi A., Todone F., Curti B., et al. Limited proteolysis and X-ray crystallography reveal the origin of substrate specificity and of the rate-limiting product release during oxidation of d-amino acids by mammalian d-amino acid oxidase. Biochemistry 36 (1997) 5624-5632
61. Adage T., Trillat A.-C., Quattropani A., Perrin D., Cavarec L., Shaw J., et al. In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol 18 (2008) 200-214
62. Ferraris D., Duvall B., Ko Y.-S., Thomas A.G., Rojas C., Majer P., et al. Synthesis and biological evaluation of d-amino acid oxidase inhibitors. J Med Chem 51 (2008) 3357-3359
63. Hashimoto K., Fujita Y., Horio M., Kunitachi S., Iyo M., Ferraris D., and Tsukamoto T. Co-administration of a d-amino acid oxidase inhibitor potentiates the efficacy of d-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry (2009) PMID 19217074
64. Horio M., Fujita Y., Ishima T., Iyo M., Ferraris D., Tsukamoto T., and Hashimoto K. Effects of d-amino acid oxidase inhibitor on the extracellular d-alanine levels and the efficacy of d-alanine on dizocilpine-induced prepulse inhibition deficits in mice. Open Clin Chem J 2 (2009) 16-21
65. Smith S.M., Uslaner J.M., Yao L., Mullins C.M., Surles N.O., Huszar S.I., et al. The behavioral and neurochemical effects of a novel d-amino acid oxidase inhibitor, 4H-thieno [3,2-b] pyrrole-5-caroboxylic acid (Compound 8) and d-serine. J Pharmacol Exp Ther 328 (2009) 921-930
66. Fang QK, Hopkins S, Jones S. Benzo[d]isoxazol-3-ol DAAO inhibitors. US 2005/0143434 A1.
67. Heffernan MLR, Foglesong RJ, Hopkins SC, Soukri M, Jones SW, Spear KL, Varney MA. Fluoro-substituted inhibitors of d-amino acid oxidase. US 2008/0004327 A1.
68. Dorsey JM, Heffernan MLR, Fang QK, Foglesong RJ, Hopkins SC, Ogbu CO, Soukri M, Spear KL. Fused heterocycles. US 2008/0004328 A1.
69. Kennis LEJ, Vanhoof GCP, Bongartz J-PAM, Luyckx MGM, Minke WE. DAAO inhibiting benzisoxazoles and their use for the treatment of mental disorders. WO/2005/089753.
70. Zhao W., Konno R., Zhou Z.-J., Yin M., and Wang Y.-X. Inhibition of d-amino acid oxidase activity induces pain relief in mice. Cell Mol Neurobiol 28 (2008) 581-591
71. Goudet C., Magnaghi V., Landry M., Nagy F., Gereau R.W., and Pin IV J.-P. Metabotropic receptors for glutamate and GABA in pain. Brain Res Rev 60 (2009) 43-56
72. Morita K., Motoyama N., Kitayama T., Morioka N., Kifune K., and Dohi T. Spinal anti-allodynia action of glycine transporter inhibitors in neuropathic pain models in mice. J Pharmacol Exp Ther 326 (2008) 633-645
73. Fukushima T., Sone Y., Mitsuhashi S., Tomiya M., and Toyo'oka T. Alteration of kynurenic acid concentration in rat plasma following optically pure kynurenine administration: a comparative study between enantiomers. Chirality 21 (2008) 468-472
74. Labrie V., Clapcote S.J., and Roder J.C. Mutant mice with reduced NMDA-NR1 glycine affinity or lack of d-amino acid oxidase function exhibit altered anxiety-like behaviors. Pharmacol Biochem Behav 91 (2009) 610-620
75. Perry K.W., Falcone J.F., Fel M.J., Ryder J.W., Yu H., Love P.L., et al. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology 55 (2008) 743-754
76. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I. et al. Common variants on chromosome 6p22.1 are associated with schizophrenia Nature 2009 doi:10.1038/nature08192.
77. International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009 doi:10.1038/nature08185.
78. Stefansson H, Ophoff RA, Steinberg S. Andreassen OA Cichon S, Rujescu D et al. Common variants conferring risk of schizophrenia. Nature 2009 doi:10.1038/nature08186.
79. Horrobin D.F. Modern biomedical research: an internally self-consistent universe with little contact with medical reality?. Nat Rev Drug Discov 2 (2003) 151-154
80. Hughes B. Novel consortium to address shortfall in innovative medicines for psychaitric disorders. Nature Rev Drug Discov 8 (2009) 523-524